Treatment plasma urine plasma urine C (2ml/kg) 0.21±0.03 2.67±0.62 9.27±0.37 785.85±116.90 A 0.65±0.12b, ad 5.52±1.39 5.22±1.68 b 469.39±62.26 b, ad G 0.21±0.02 2.37±0.46 7.57±0.55 b 545.93±69.92 ad AG 0.11±0.09 3.19±0.45 6.61±1.16 237.74±45.50 K 0.09±0.01b 1.77±0.13 9.44±0.42 336.41±49.71 b KAG 0.35±0.12 ac 6.37±0.90 ac 9.39±1.09 251.92±23.39 D 0.26± 0.03 2.64± 0.46 11.23± 0.49 b 473.33±51.56 b DG 0.08± 0.13 ab 4.56± 0.84 ab 7.94± 0.51 ab 276.96± 49.88 ab DGA 0.23±0.02 3.98±0.44 11.62±1.67 392.77±23.46 KDGA 0.19±0.01 1.57±0.24 ab 8.67±0.69 499.13±59.10 Values are mean + SEM. (n=5 per group). bp<0.05 significantly different from the control, abp<0.05 significantly different from the diabetic group treated with glibenclamide and amlodipine , acp<0.05 significantly different from the potassium adapted group and cp<0.05 significantly different from the normal group treated with amlodipine and glibenclamide. C: Control (normal saline group) A: Normal group treated with amlodipine G : Normal group treated with glibenclamide AG: Normal group treated with both amlodipine and glibenclamide K: Potassium adapted group D: Diabetic group DG: Diabetic group treated with glibenclamide KAG: Potassium adapted treated with both glibenclamide and amlodipine DGA: Non-adapted diabetic group treated with both glibenclamide and amlodipine KDAG: potassium adapted diabetic group treated with both amlodipine and glibenclamide

Table 4: Effects of potassium-adaptation on creatinine and urea of normal and streptozotocin induced- diabetic rats treated with amlodipine (5 mg/kg) and glibenclamide (5 mg/kg).

Goto home»